Immunotherapies for advanced melanoma: as promising as they are expensive?
Menée dans un contexte européen, cette étude analyse le rapport coût-efficacité des nouvelles immunothérapies pour le traitement des patients atteints d'un mélanome de stade avancé
Here we analyse the economic evidence on new immunotherapies for advanced melanoma, focusing on the European setting. This analysis is preceded by a clinical background of the pathology and the immunotherapies already approved
http://journals.sagepub.com/doi/abs/10.1177/0141076817731094 2017